This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Sep;10(5):336-7.

doi: 10.1007/s11910-010-0130-6.

Tarenflurbil in patients with mild Alzheimer's disease

Affiliations

Affiliation

¹ Sally Kerlin Professor of Neurology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. ksm1@columbia.edu

PMID: 20571933
DOI: 10.1007/s11910-010-0130-6

Comment

Tarenflurbil in patients with mild Alzheimer's disease

Karen Marder. Curr Neurol Neurosci Rep. 2010 Sep.

. 2010 Sep;10(5):336-7.

doi: 10.1007/s11910-010-0130-6.

Author

Affiliation

¹ Sally Kerlin Professor of Neurology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. ksm1@columbia.edu

PMID: 20571933
DOI: 10.1007/s11910-010-0130-6

No abstract available

PubMed Disclaimer

Comment on

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group. Green RC, et al. JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866. JAMA. 2009. PMID: 20009055 Free PMC article. Clinical Trial.

References

1. Lancet Neurol. 2008 Jun;7(6):483-93 - PubMed
1. Curr Neurol Neurosci Rep. 2009 Sep;9(5):368-76 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer